A Phase 3 interventional study of risankizumab in Psoriasis, sponsored by AbbVie. Completed at 233 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one has the largest enrollment, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,170 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 2nd largest by enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2017, is one of 31 in phase 3, and was the 43rd registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
This is a Phase 3, single-arm, multicenter open label extension (OLE) study designed to investigate the long-term safety and efficacy of 150 mg risankizumab in the treatment of moderate to severe chronic plaque psoriasis. Approximately 2200 participants who meet the entry criteria are planned to be enrolled in this study, rolling over from the preceding Phase 2/3 studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, participant must be either , OR permanently surgically sterile OR for women of childbearing potential practicing at least one protocol specified method of , starting at Baseline through at least 20 weeks after the last dose of study drug.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive risankizumab administered by subcutaneous injection.
Biological: risankizumab
Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
Also known as: ABBV-066, Skyrizi, BI 655066
Number of Participants With Serious Adverse Events and Non-Serious Adverse Events
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Time frame: Median follow-up time of 1905 days
Participants from Studies M16-008 (NCT02684370), M16-010 (NCT02694523), M15-995 (NCT02684357), M16-178 (NCT03255382), M16-009 (NCT02203851), M15-992 (NCT02672852), and M16-004 (NCT03000075) entered this open-label extension (OLE) study from 232 sites across 17 countries (Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Japan, Mexico, Poland, Portugal, Republic of Korea, Spain, Sweden, Taiwan, and US).
| Milestone | Risankizumab 150 mg |
|---|---|
| Started | 2170 |
| Completed | 1601 |
| Not completed | 569 |
| Withdrew: Adverse event | 142 |
| Withdrew: Withdrawal by subject | 155 |
| Withdrew: Lost to follow-up | 144 |
| Withdrew: Covid-19 infection | 2 |
| Withdrew: Covid-19 logistical restrictions | 9 |
| Withdrew: Other, not specified | 117 |
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
| Participants | Risankizumab 150 mg |
|---|---|
| Serious Adverse Events | 435 |
| Non-serious Adverse Events | 1215 |
Collected over Median follow-up time of 1905 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risankizumab 150 mg | 28/2,170 (1.3%) | 435/2,170 (20%) | 1,215/2,170 (56%) |
| Event | Risankizumab 150 mg |
|---|---|
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 17/2170 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 13/2170 |
| COVID-19Infections and infestations | 13/2170 |
| ATRIAL FIBRILLATIONCardiac disorders | 9/2170 |
| CORONARY ARTERY DISEASECardiac disorders | 9/2170 |
| MYOCARDIAL INFARCTIONCardiac disorders | 9/2170 |
| NEPHROLITHIASISRenal and urinary disorders | 8/2170 |
| COVID-19 PNEUMONIAInfections and infestations | 7/2170 |
| PNEUMONIAInfections and infestations | 7/2170 |
| SYNCOPENervous system disorders | 7/2170 |
| Event | Risankizumab 150 mg |
|---|---|
| NASOPHARYNGITISInfections and infestations | 480/2170 |
| COVID-19Infections and infestations | 360/2170 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 312/2170 |
| HYPERTENSIONVascular disorders | 227/2170 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 217/2170 |
| HEADACHENervous system disorders | 134/2170 |
| BACK PAINMusculoskeletal and connective tissue disorders | 124/2170 |
| Age, Customized(Participants) | Risankizumab 150 mg |
|---|---|
| < 40 years | 658 |
| 40 - < 65 years | 1264 |
| >= 65 years | 248 |
| Sex: Female, Male(Participants) | Risankizumab 150 mg |
|---|---|
| Female | 634 |
| Male | 1536 |
| Ethnicity (NIH/OMB)(Participants) | Risankizumab 150 mg |
|---|---|
| Hispanic or Latino | 257 |
| Not Hispanic or Latino | 1913 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Risankizumab 150 mg |
|---|---|
| American Indian or Alaska Native | 15 |
| Asian | 466 |
| Native Hawaiian or Other Pacific Islander | 9 |
| Black or African American | 50 |
| White | 1622 |
| More than one race | 8 |
| Unknown or Not Reported | 0 |
Showing the first 100 of 233 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Feb 2017 to primary completion in Nov 2023, 81 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 81 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab